STE

STERIS plc

Add to Watchlist

Advanced Chart

242.850

+6.61(2.798%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

244.250

Open

238.600

VWAP

242.64

Vol

863.79K

Mkt Cap

23.92B

Low

236.830

Amount

209.59M

EV/EBITDA(TTM)

16.26

Total Shares

98.85M

25.12B

EV/OCF(TTM)

18.50

P/S(TTM)

4.80

STERIS Plc is a provider of products and services that support patient care with an emphasis on infection prevention. Its segments include Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Its Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. AST segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities, and integrated sterilization equipment and control systems. Its Life Sciences segment provides a comprehensive offering of products and services designed to support biopharmaceutical and medical device research and manufacturing facilities, in particular those focused on aseptic manufacturing. Its portfolio includes a full suite of consumable products, equipment maintenance, specialty services, and capital equipment.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q4

FY2026Q3

FY2026Q2

1.58B

+6.6%

2.883

+5.21%

1.47B

+6.94%

2.540

+9.48%

1.42B

+6.57%

2.364

+10.48%

Estimates Revision

The market is revising Upward the revenue expectations for STERIS plc (STE) for FY2026, with the revenue forecasts being adjusted by 0.69% over the past three months. During the same period, the stock price has changed by 7.52%.

Revenue Estimates for FY2026

Revise Upward

+0.69%

In Past 3 Month

EPS Estimates for FY2026

Revise Upward

+1.68%

In Past 3 Month

Stock Price

Go Up

+7.52%

In Past 3 Month

7 Analyst Rating

10.56% Upside

Wall Street analysts forecast STE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STE is 268.50 USD with a low forecast of 250.00 USD and a high forecast of 280.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

2 Hold

0 Sell

Moderate Buy

10.56% Upside

Current: 242.850

Low

250.00

Averages

268.50

High

280.00

10.56% Upside

Current: 242.850

Low

250.00

Averages

268.50

High

280.00

KeyBanc

Brett Fishbin

Overweight

maintain

$277 -> $288

2025-07-22

Reason

KeyBanc

Brett Fishbin

Price Target

$277 -> $288

2025-07-22

maintain

Overweight

Reason

KeyBanc analyst Brett Fishbin raised the firm's price target on Steris to $288 from $277 and keeps an Overweight rating on the shares. The firm notes that underlying MedTech trends appear positive heading into Q2 earnings season, and KeyBanc believes sub-sector underperformance this year has been more attributable to macro uncertainties such as the impact of tariffs. Specifically, the firm's Key First Look Data has indicated a high-single digit volume growth in the hospital category through Q2. KeyBanc continues to view tariffs as the biggest overhang to the group, but consensus estimates at least now incorporate the known base-case impacts.

Morgan Stanley

Equal Weight -> Overweight

upgrade

$260 -> $276

2025-07-15

Reason

Morgan Stanley

Price Target

$260 -> $276

2025-07-15

upgrade

Equal Weight -> Overweight

Reason

Morgan Stanley upgraded Steris to Overweight from Equal Weight with a price target of $276, up from $260. The firm's work on the potential margin gains from the shift to E-Beam, consolidation of volumes and pricing power on NESHAP compliance costs, improving bioprocessing trends, and potential tailwind from Olympus' import ban into the U.S., all leave the firm more positive on Steris, the analyst tells investors in a research note.

Jefferies

David Windley

Hold

initiated

$263

2025-05-29

Reason

Jefferies

David Windley

Price Target

$263

2025-05-29

initiated

Hold

Reason

Jefferies analyst David Windley initiated coverage of Steris with a Hold rating and $263 price target. The next few years will pit the company's "resilient business against a potential wave of highly disruptive" healthcare policy changes, the analyst tells investors in a research note. The firm says 14M Medicaid and healthcare exchange lives losing coverage likely presents a multi-percent volume headwind for the company.

Citizens JMP

Outperform

maintain

$265 -> $280

2025-05-16

Reason

Citizens JMP

Price Target

$265 -> $280

2025-05-16

maintain

Outperform

Reason

Citizens JMP raised the firm's price target on Steris to $280 from $265 and keeps an Outperform rating on the shares. Steris ended fiscal 2025 with a strong quarter that included a marginal beat on the top line and 5% bottom-line upside, the analyst tells investors in a research note. The company has built an impressive track record of consistent execution and the portfolio remains largely non-elective in nature, and fiscal 2026 should be another solid year for the company and the stock, Citizens says.

JMP Securities

David Turkaly

Buy

Reiterates

$265

2025-04-10

Reason

JMP Securities

David Turkaly

Price Target

$265

2025-04-10

Reiterates

Buy

Reason

Needham

Mike Matson

Hold

Reiterates

n/a

2025-04-07

Reason

Needham

Mike Matson

Price Target

n/a

2025-04-07

Reiterates

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for STERIS plc (STE.N) is 22.03, compared to its 5-year average forward P/E of 24.91. For a more detailed relative valuation and DCF analysis to assess STERIS plc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

24.91

Current PE

22.03

Overvalued PE

27.54

Undervalued PE

22.27

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

16.90

Current EV/EBITDA

15.00

Overvalued EV/EBITDA

18.68

Undervalued EV/EBITDA

15.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

4.12

Current PS

3.78

Overvalued PS

4.57

Undervalued PS

3.67